Home > Insider Trading > Filing (0001144204-14-013331)

Filing Details

Accession Number:: 0001144204-14-013331
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-03-04 17:53:52
Reporting Period:: 2014-02-28

Filing Date:: 2014-03-04
Accepted Time:: 2014-03-04 17:53:52
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1232524	Jazz Pharmaceuticals Plc	JAZZ	Pharmaceutical Preparations (2834)	981032470

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1253886	G Patrick Enright	C/O Longitude Capital Partners, Llc 800 El Camino Real, Suite 220 Menlo Park CA 94025		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2014-02-28	929,243	$4.00	929,243	No	4	X	Indirect	By Longitude Venture Partners, L.P.
Ordinary Shares	Acquisiton	2014-02-28	18,624	$4.00	18,624	No	4	X	Indirect	By Longitude Capital Associates, L.P.
Ordinary Shares	Disposition	2014-02-28	686	$165.94	928,557	No	4	S	Indirect	By Longitude Venture Partners, L.P.
Ordinary Shares	Disposition	2014-02-28	14	$165.94	18,610	No	4	S	Indirect	By Longitude Capital Associates, L.P.
Ordinary Shares	Disposition	2014-02-28	28	$164.50	928,529	No	4	S	Indirect	By Longitude Venture Partners, L.P.
Ordinary Shares	Disposition	2014-02-28	1	$164.50	18,609	No	4	S	Indirect	By Longitude Capital Associates, L.P.
Ordinary Shares	Disposition	2014-02-28	3,645	$162.94	924,884	No	4	S	Indirect	By Longitude Venture Partners, L.P.
Ordinary Shares	Disposition	2014-02-28	71	$162.94	18,538	No	4	S	Indirect	By Longitude Capital Associates, L.P.
Ordinary Shares	Disposition	2014-02-28	39,241	$161.93	885,643	No	4	S	Indirect	By Longitude Venture Partners, L.P.
Ordinary Shares	Disposition	2014-02-28	787	$161.93	17,751	No	4	S	Indirect	By Longitude Capital Associates, L.P.
Ordinary Shares	Disposition	2014-02-28	8,866	$160.76	876,777	No	4	S	Indirect	By Longitude Venture Partners, L.P.
Ordinary Shares	Disposition	2014-02-28	180	$160.77	17,571	No	4	S	Indirect	By Longitude Capital Associates, L.P.
Ordinary Shares	Disposition	2014-02-28	20,977	$159.91	855,800	No	4	S	Indirect	By Longitude Venture Partners, L.P.
Ordinary Shares	Disposition	2014-02-28	423	$159.91	17,148	No	4	S	Indirect	By Longitude Capital Associates, L.P.
Ordinary Shares	Disposition	2014-02-28	28,070	$159.03	827,730	No	4	S	Indirect	By Longitude Venture Partners, L.P.
Ordinary Shares	Disposition	2014-02-28	559	$159.03	16,589	No	4	S	Indirect	By Longitude Capital Associates, L.P.
Ordinary Shares	Disposition	2014-02-28	435,588	$150.50	392,142	No	4	S	Indirect	By Longitude Venture Partners, L.P.
Ordinary Shares	Disposition	2014-02-28	8,731	$150.50	7,858	No	4	S	Indirect	By Longitude Capital Associates, L.P.
Ordinary Shares	Disposition	2014-03-03	300	$147.87	11,461	No	4	S	Indirect	By Longitude Capital Partners, LLC
Ordinary Shares	Disposition	2014-03-03	2,700	$148.55	8,761	No	4	S	Indirect	By Longitude Capital Partners, LLC
Ordinary Shares	Disposition	2014-03-03	3,700	$149.42	5,061	No	4	S	Indirect	By Longitude Capital Partners, LLC
Ordinary Shares	Disposition	2014-03-03	1,166	$150.45	3,895	No	4	S	Indirect	By Longitude Capital Partners, LLC
Ordinary Shares	Disposition	2014-03-03	3,895	$153.80	0	No	4	S	Indirect	By Longitude Capital Partners, LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	X	Indirect	By Longitude Venture Partners, L.P.
No	4	X	Indirect	By Longitude Capital Associates, L.P.
No	4	S	Indirect	By Longitude Venture Partners, L.P.
No	4	S	Indirect	By Longitude Capital Associates, L.P.
No	4	S	Indirect	By Longitude Venture Partners, L.P.
No	4	S	Indirect	By Longitude Capital Associates, L.P.
No	4	S	Indirect	By Longitude Venture Partners, L.P.
No	4	S	Indirect	By Longitude Capital Associates, L.P.
No	4	S	Indirect	By Longitude Venture Partners, L.P.
No	4	S	Indirect	By Longitude Capital Associates, L.P.
No	4	S	Indirect	By Longitude Venture Partners, L.P.
No	4	S	Indirect	By Longitude Capital Associates, L.P.
No	4	S	Indirect	By Longitude Venture Partners, L.P.
No	4	S	Indirect	By Longitude Capital Associates, L.P.
No	4	S	Indirect	By Longitude Venture Partners, L.P.
No	4	S	Indirect	By Longitude Capital Associates, L.P.
No	4	S	Indirect	By Longitude Venture Partners, L.P.
No	4	S	Indirect	By Longitude Capital Associates, L.P.
No	4	S	Indirect	By Longitude Capital Partners, LLC
No	4	S	Indirect	By Longitude Capital Partners, LLC
No	4	S	Indirect	By Longitude Capital Partners, LLC
No	4	S	Indirect	By Longitude Capital Partners, LLC
No	4	S	Indirect	By Longitude Capital Partners, LLC

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Warrant (right to buy)	Disposition	2014-02-28	929,243	$0.00	929,243	$4.00
Ordinary Shares	Warrant (right to buy)	Disposition	2014-02-28	18,624	$0.00	18,624	$4.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2009-07-07	2016-07-06	No	4	X	Indirect
0	2009-07-07	2016-07-06	No	4	X	Indirect

Footnotes

Reflects acquisition of ordinary shares upon exercise of in-the-money warrant and is therefore exempt from the operation of Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-6(b).
On February 28, 2014, Longitude Ventures Partners, L.P.("LVP") and Longitude Capital Associates, L.P.("LCA") distributed to their partners all of the ordinary shares of which they were the record holder prior to the exercise of warrants reflected in this report, totaling 768,670 ordinary shares held of record by LVP and 15,422 shares held of record by LCA. The reporting person reported beneficial ownership over all such shares in his prior reports filed under Section 16(a) of the Securities Exchange Act of 1934, as amended(the "Exchange Act"). The general partner of each of LVP and LCA, Longitude Capital Partners, LLC("LCP"), received an aggregate of 11,761 ordinary shares in such distributions, consisting of 11,530 ordinary shares from LVP and 231 ordinary shares from LCA.
The reporting person disclaims beneficial ownership of the securities of Jazz Pharmaceuticals plc held of record by LVP, LCA and LCP, except to the extent of his pecuniary interest therein.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $163.48 to $162.50. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $163.48 to $162.50. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $162.43 to $161.45. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $162.43 to $161.45. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $161.37 to $160.41. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $161.37 to $160.41. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $160.25 to $159.26. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $160.25 to $159.26. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $159.24 to $159. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $159.24 to $159. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $147.82 to $147.90. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $148.02 to $148.905. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $148.95 to $149.91. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $149.99 to $150.98. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $153.535 to $154.055. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.